Mori Takuya, Tanaka Hiroaki, Deguchi Sota, Miki Yuichiro, Yoshii Mami, Tamura Tatsuro, Toyokawa Takahiro, Lee Shigeru, Muguruma Kazuya, Ohira Masaichi
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Cancer Diagn Progn. 2022 May 3;2(3):384-390. doi: 10.21873/cdp.10121. eCollection 2022 May-Jun.
BACKGROUND/AIM: Recently, several studies have reported that CD103 T cells are associated with antitumor immunity in gastric cancer (GC). However, the significance of CD103 T cells in Borrmann type 4 GC remains unclear. The aim of this study is to assess the association of CD103 T cells with type 4 GC.
Tissue samples obtained from surgically resected specimens of patients with type 4 GC were collected, and immunohistochemical staining was performed to detect the presence of CD103 T cells.
A total of 46 patients were analyzed. In some patients, high CD103 expression was observed, and patients with high CD103 expression tended to have a better prognosis than those with low CD103 expression. In particular, for patients who receive doublet chemotherapy after surgery, high CD103 expression was associated with a good prognosis.
CD103 T cells may be a prognostic marker in type 4 GC.
背景/目的：最近，多项研究报道CD103⁺ T细胞与胃癌（GC）的抗肿瘤免疫相关。然而，CD103⁺ T细胞在Borrmann 4型GC中的意义仍不明确。本研究的目的是评估CD103⁺ T细胞与4型GC的相关性。
收集4型GC患者手术切除标本的组织样本，进行免疫组织化学染色以检测CD103⁺ T细胞的存在。
共分析了46例患者。在部分患者中观察到CD103高表达，CD103高表达的患者预后往往优于CD103低表达的患者。特别是对于术后接受双联化疗的患者，CD103高表达与良好预后相关。
CD103⁺ T细胞可能是4型GC的一个预后标志物。
